P2X7 purinoceptor promotes survival or cytotoxicity depending on extracellular adenosine triphosphate (ATP) stimulus intensity controlling its ion channel or P2X7-dependent large pore (LP) functions. Mechanisms governing this operational divergence and functional idiosyncrasy are ill-understood. We have discovered a feedback loop where sustained activation of P2X7 triggers release of active matrix metalloproteinase 2 (MMP-2), which halts ion channel and LP responses via the MMP-2-dependent receptor cleavage. This mechanism operates in cells as diverse as macrophages, dystrophic myoblasts, P2X7-transfected HEK293, and human tumour cells. Given that serum-born MMP-2 activity also blocked receptor functions, P2X7 responses in vivo may decrease in organs with permeable capillaries. Therefore, this mechanism represents an important fine-tuning of P2X7 functions, reliant on both cell-autonomous and extraneous factors. Indeed, it allowed evasion from the ATP-induced cytotoxicity in macrophages and human cancer cells with high P2X7 expression levels. Finally, we demonstrate that P2X7 ablation eliminated gelatinase activity in inflamed dystrophic muscles in vivo. Thus, P2X7 antagonists could be used as an alternative to highly toxic MMP inhibitors in treatments of inflammatory diseases and cancers.
Introduction
High concentration of extracellular adenosine triphosphate (eATP), which normally occurs in damaged tissues only, is one of the danger-associated molecular patterns. High (mM) eATP concentrations signal through the P2X7 purinergic receptor. Unlike other P2Xs, it is fully activated by significantly higher eATP and triggers the 'danger' response in inflammatory cells (de Torre-Minguela et al., 2016) . Therefore, P2X7 is a therapeutic target in inflammatory diseases (Bartlett et al., 2014) . An interesting property of P2X7 is that this ATP-gated ion channel, under some conditions, can trigger non-specific passage of molecules of up to 900 Da. While the mechanism of this large pore (LP) opening is still disputed (Browne et al., 2013; Pippel et al., 2017) , it is undoubtedly associated with cell death via a range of unique pathways (e.g. aponecrosis, autosis, etc.) and, as we recently discovered, with autophagy . Further complexity of P2X7 response is illustrated by the findings that low-level eATP stimulation of this purinoceptor can result in tonic/trophic effects such as increased cellular glycolysis, proliferation, migration, and invasion (Amoroso et al., 2012; Rigato et al., 2012; Xia et al., 2015) . Studying purinergic abnormalities in Duchenne muscular dystrophy (DMD) (Young et al., 2012; Sinadinos et al., 2015) , we observed that myoblasts carrying a premature stop codon in the Dmd gene can display two markedly different modes of response to eATP: one extremeautophagic cell death and the second, a cellular detachment response. Therefore, we have sought to elucidate the mechanism(s) governing this response diversity and allowing cells expressing high P2X7 levels to survive in the high eATP environment. We found the LP opening to be triggering the release of active matrix metalloproteinase 2 (MMP-2). Interestingly, while P2X7 activation was previously linked to MMP-9 release (Gu and Wiley, 2006) and MMP-2 and MMP-9 are both the gelatinases (Visse and Nagase, 2003; Page-McCaw et al., 2007) , only the MMP-2 release is of functional consequences to the cell and the P2X7 receptor itself: we found P2X7-evoked MMP-2 activity to regulate cell migration, invasion and remodelling of extracellular matrix and its receptors. We demonstrate, for the first time, P2X7-dependent cleavage of β-dystroglycan, a dystrophin-associated ECM receptor, in both myoblasts and macrophages. Importantly, we found that active MMP-2 released following LP formation also cleaves P2X7 receptors. Therefore, we identified a novel feedback loop mechanism in which high eATP triggers P2X7 LP formation that regulates active MMP-2 release, which, in turn, halts the receptor function. Importantly, this mechanism afforded an evasion path from LP-induced cytotoxicity in cancer cells harbouring high P2X7 levels.
Results

Dystrophic myoblasts display increased MMP-2 activity, which is released upon P2X7 activation
The quantitative phosphoproteomic analysis of ATP-treated mdx myobalsts (from the DMD mdx mouse model) revealed significant differences in the phosphorylation of the ERM proteins: Ezrin, Radixin, and Moesin (Supplementary Figure S1A) , with established roles in cell adhesion and migration (Yonemura et al., 1998; DesMarais et al., 2005; Li et al., 2007) . Therefore, we performed cell migration and invasion assays and found that dystrophic cells treated with BzATP (300 μM) became polarized in their direction of migration, whereas WT myoblasts moved more randomly (Supplementary Figure S1B) . Moreover, significantly increased migration and invasion rates through gelatin were observed for dystrophic myoblasts treated with 300 μM BzATP (Supplementary Figure S1C , left panel). These responses were completely blocked by the addition of the P2X7 antagonist A438079 or extracellular Ca 2+ chelator EDTA (Supplementary Figure S1C , right panel).
Given this invasion through gelatin, where MMPs have been implicated as downstream mediators (Qiu et al., 2014; Xia et al., 2015) , we investigated the MMP activity in these cells. P2X7-dependent MMP-9 release has been documented in peripheral blood mononuclear cells of mouse and human origin (Gu and Wiley, 2006) . Surprisingly, in gel zymography (IGZ) (Vandooren et al., 2013) with gelatin immobilized in polyacrylamide gels revealed that dystrophic myoblasts display significantly elevated MMP-2 activity compared to WT myoblasts, while MMP-9 activity actually appeared reduced in dystrophic cell extracts ( Figure 1A and Supplementary Figure S2) . Where referred to throughout, 'MMP-2 activity' is used to indicate the presence of the enzymatically active mature form of MMP-2. Indeed, western blotting analysis of these cell extracts revealed that MMP-2 protein levels were significantly lower in mdx than WT myoblasts ( Figure 1B ) thus excluding any possibility of a nonspecific activation of MMP-2 during IGZ. Furthermore, MMP-9 protein expression was comparable across all samples ( Figure 1B) . Therefore, further investigations were focused on MMP-2. IGZ using cell pellets and supernatants collected from ATP stimulated mdx cells showed MMP-2 activity in cell pellets to fall over a period of 60 min following P2X7 activation, which correlated with the increased MMP-2 activity in supernatants ( Figure 1C and D) . Whilst MMP-9 did show a reduced signal in the pellet at 15 min, this was the same for both mdx and WT cells (the latter not expressing P2X7) and therefore not a P2X7-dependent response. BzATP (a more selective P2X7 agonist) evoked the same pattern of MMP-2 release and the concentration range triggering this effect was consistent with the P2X7 receptor activation (Supplementary Figure S3) . Immunoblotting using anti-MMP-2 antibody confirmed the release of MMP-2 protein from cells ( Figure 1E and F) into supernatants ( Figure 1G and H). Elevated MMP-2 activity in supernatants was later followed by some LDH release indicating a degree of cell deaths ( Figure 1H ). Finally, MMP-2 activity changes were eliminated by the P2X7 LP antagonist A438079 treatment ( Figure 1I and J), further confirming this effect to be P2X7-specific.
MMP activity triggered by P2X7 pore formation leads to cleavage of β-dystroglycan and CD44
We next considered potential MMP-2 targets; given that β-dystroglycan in muscle is a well-known ECM receptor involved in cell adhesion and motility (Thompson et al., 2008) and that it has been shown to be a target for MMPs in different tissues (Yamada et al., 2001; Michaluk et al., 2007; Sbardella et al., 2015) we analysed this protein by western blotting. In dystrophic but not wild-type myoblasts the P2X7 activation, shown previously to cause MMP-2 release, resulted in β-dystroglycan cleavage (Figure 2A and B) . This effect was P2X7 dependent as it was absent in mdx/P2X7
-/-cells (Xia et al., 2015) lacking P2X7 receptors ( Figure 4C ). The resulting disruption of the link between the ECM and the cell membrane dystroglycan may explain the cell detachment response and enhanced migration of dystrophic cells (Supplementary Figure S1) . CD44 is another known MMP target (Chetty et al., 2012) , which is also an interacting partner of the ERM proteins (Visse and Nagase, 2003) . Moreover, CD44 cleavage products have been shown to bind to and augment activation of P2X7 receptors (Moura et al., 2015) . We therefore hypothesized that a similar mechanism may operate in dystrophic cells. Interestingly, while we found that CD44 cleavage did occur in mdx myoblasts ( Figure 2C and D), it was not associated with the expected augmentation of P2X7 functions. In fact, we uncovered downregulation of P2X7 responses subsequent to MMP release.
MMP-2 is a suppressor of P2X7 receptor functions
In our previous work, we found P2X7-dependent pore formation and autophagic cell death to be completely absent in the presence of serum (>5%) in the medium Young et al., 2015) . Given that the serum is a rich source of proteases including MMPs, cathepsins, and trypsins (Artigas et al., 1981; Thrailkill et al., 2005; Weitoft et al., 2015) , we investigated the possibility that the serum MMP-2 is a critical factor in mediating this P2X7 response inhibition. Indeed, P2X7-dependent MMP-2 release, measured by the decreasing activity in cell pellets, was only observed in serum-free media and completely blocked when myoblasts or macrophages were analysed in high serum Figure 1 MMP-2 activity is constitutively upregulated in dystrophic myoblasts and is released following P2X7 activation. (A) IGZ showed MMP-2 activity being significantly upregulated in dystrophic cells, whilst MMP-9 activity being downregulated. (B) Western blot showed MMP-2 and 9 protein levels not corresponding with their activity. (C) IGZ revealed that in dystrophic but not WT myoblasts ATP (3 mM) produced a rapid and significant release of active MMP-2. (D) Quantification of MMP-2 activity in IGZ from pellets and supernatants (SuperN) of dystrophic myoblasts. Immunoblot analysis using anti-MMP-2 antibody confirmed the decrease of MMP-2 in mdx cell pellets. (E) MMP-2 protein was released from dystrophic myoblasts following BzATP (0.5 mM) treatment; this effect was blocked by the P2X7 LP antagonist A438079 (10 μM). (F) Quantification of MMP-2 protein levels in cell pellets following BzATP treatment with or without A438079. (G) MMP-2 protein was concomitantly detectable in concentrated cell culture supernatants from treated cells. (H) Time-dependent relationship between MMP-2 protein and LDH levels in mdx myoblast supernatants following BzATP treatment. (I) P2X7 involvement in MMP-2 release was confirmed in IGZ using pellets and supernatants from myoblasts treated with the selective P2X7 agonist, BzATP with or without 10 min preincubation with 10 μM P2X7 antagonist A438079. (J) Quantification of MMP-2 activity in mdx myoblast supernatants following BzATP treatment over 60 min. Where three replicates are shown, these represent three independent biological samples. Actin and total protein (Coomassie staining) band intensities are shown as loading controls. Molecular weight markers in IGZ are shown as a guide only. *P < 0.05, ***P < 0.001.
( Figure 3A ). P2X7 LP function measured by EtBr uptake was also inhibited by the increasing serum concentrations but only if the serum contained active MMP-2 ( Figure 3B and C). Titration of MMP-2 inhibitor I (Millipore) showed that at 67 μM it effectively blocked MMP-2 ( Figure 3D ) without affecting MMP-9 activity. Preincubation of cells with this compound resulted in significantly enhanced P2X7-evoked EtBr uptake ( Figure 3E ). Importantly, active MMP-2 (recombinant protein or present in a serum) inhibited specific P2X7 calcium channel activity too ( Figure 3F ). In contrast, inhibitors of cathepsins and trypsins, having, no effect on MMP-2 activity (Supplementary Figure S4A) , were completely ineffective in altering P2X7 functions (Supplementary Figure S4B) . This confirmed the specific effect of MMP-2 on P2X7 ( Figure 3G ).
P2X7-dependent MMP-2 release occurs in macrophages and P2X7-transfected HEK293 cells
Next, we studied whether this mechanism is universal. Given the known roles of P2X7 in macrophages, we examined P2X7-dependent MMP-2 release in RAW264 mouse macrophages ( Figure 4A Figure 4H ). Importantly, these HEK P2X7 showed no MMP-9 activity thus confirming the response to be MMP-2 specific. Macrophages displayed a more rapid release of MMP-2 in response to BzATP ( Figure 4A ), consistent with higher P2X7 receptor expression levels in these cells when compared to dystrophic myoblasts . This response was again completely abolished in the presence of high serum ( Figure 4A and B). Crucially, double negative primary macrophages isolated from mdx/P2X7
-/-mice did not display intracellular MMP-2 activity or extracellular MMP-2 release in response to BzATP treatment, confirming the response to be P2X7 dependent ( Figure 4C ). Macrophages also displayed β-dystroglycan cleavage, which was completely absent in P2X7 knockout-derived cells (KO, Figure 4E ). Indeed, this response was more rapid than in myoblasts; macrophages displayed complete cleavage of the 43 kDa β-dystroglycan band within 30 min of BzATP stimulation, which may again reflect the increased level of P2X7 expression in these cells. Interestingly, transfection of HEK cells with P2X7 (Supplementary Figure S5 ) was both necessary and sufficient to confer P2X7-dependent MMP-2 release from these cells in response to BzATP ( Figure 4H ).
P2X7 is a proteolytic target for MMP-2
Given the MMP-2 release in response to P2X7 activation and that this lead to downregulation of receptor functions, we Quantification of native and cleaved CD44 protein levels following BzATP treatment in mdx myoblasts. This P2X7-dependent degradation was absent in WT myoblasts, which lack P2X7 expression (A and C, upper panels). TA, tibialis anterior. *P < 0.05, ***P < 0.001. investigated the possibility that P2X7 itself could be a target for MMP-2 cleavage. CleavPredict (Sandford Burnham) analysis revealed multiple putative cleavage sites for MMP-2 in mouse and human P2X7 sequences (Supplementary Figure S6A) . Therefore, we performed western blotting with anti-P2X7 antibody in samples from BzATP-treated cells under conditions where MMP-2 is released. We found reduced levels of the 80 kDa P2X7 band 60 min after BzATP treatment ( Figure 5A ) and increasing amounts of a potential C-terminal cleavage product (∼35 kDa) occurring after 30 min. This cleavage product was not present in samples pre-incubated with MMP-2 Inhibitor I ( Figure 5A , lower panel). Significant cleavage was already observed 15 min following P2X7 activation ( Figure 5C ). For a direct confirmation, protein lysates from mdx myoblasts, peritoneal macrophages and HEKP2X7 cells were incubated with activated or inactive recombinant mouse MMP-2 for 30 min at 37°C. We observed a cleavage product of the same molecular weight as that seen in BzATP-treated cells, when active recMMP-2 was used. This band was absent in samples treated with inactive recMMP-2 ( Figure 5E ). The size of this cleavage product (∼35 kDa) corresponded with predicted cleavage sites at positions 277 and 298 ( Figure 5G ). The first site is particularly well conserved across species (Supplementary Figure S6B) . Combination of data obtained using recMMP-2 and its blocker in cells and in protein extracts confirmed that P2X7 is a trigger for the release as well as the proteolytic target for MMP-2. (with high levels of MMP activity) produced no detectable change in MMP-2 activity in cell pellets irrespective of the ATP concentration used (0.1-1 mM) and did not induce any P2X7-dependent EtBr uptake (B, bottom panel). In the absence of serum, MMP-2 activity was released from cells (activity decreased in cell pellets) following stimulation with increasing ATP concentrations (A, lower panel). (B) Unlike bovine (FBS) and horse (DHS) sera containing high MMP activity, the serum-replacement medium (KSR) is MMP-free and in KSR but not in FBS or DHS, the EtBr fluorescence was observed. (C) Quantification of EtBr uptake in mdx myoblasts treated with ATP in different sera concentrations. (D) Specific MMP-2 inhibitor caused a dose-dependent reduction of MMP-2 activity, which (E) correlated with enhanced EtBr uptake and confirmed the role of MMP-2 in this response. EtBr uptake was also reversed by the addition of active recombinant mouse MMP-2 or MMP-2-containing serum (FBS, 5%). (F) Calcium influx via P2X7 channels was also inhibited in the presence of recombinant or serum-born MMP-2 activity. (G) Diagrammatic representation summarizing the proposed temporal relationship between P2X7 receptor function and MMP-2 activity. Scale bar = 10 μm. *P < 0.05, ***P < 0.001. MMP-2 cleavage as an off switch for P2X7 activity j 233 MMP-2 release blocks P2X7 pore formation and ATP-induced death in tumour cells P2X7 has been found upregulated in tumours including as diverse types as breast (Ma, 2015) , brain (Monif et al., 2014) , and prostate (Qiu et al., 2014) . Tumour cells were found to benefit from increased mitochondrial metabolic activity and growth caused by increased P2X7 expression (Di Virgilio et al., 2009) . However, there is a question: How these cells avoid death associated with this high-level P2X7 expression and activation in high eATP environments? Discovery of the MMP-2-dependent P2X7 cleavage prompted us to investigate whether tumour cells exploit this mechanism to evade the cell death. Firstly, we interrogated the Cancer Genome Atlas database and found that overexpression of P2X7 and MMP-2 in prostate cancer samples coincide (Supplementary Figure S7) . We then confirmed very high levels of P2X7 receptor expression in the human LNCaP prostate cancer cells ( Figure 6A) . However, EtBr uptake in these cells following 30 min stimulation with 3 mM ATP was not as strong as would be expected from such high P2X7 expression levels ( Figure 6B) and there was no cell rounding, detachment, or blebbing (data not shown). In contrast, a significant P2X7-dependent EtBr uptake was observed when MMP-2 activity was blocked ( Figure 6B) . IGZ showed constitutively high levels of MMP-2 being released from LNCaPs into the supernatant, which was further elevated in the presence of P2X7 agonists ( Figure 6C ). This high extracellular MMP-2 activity coincided with constitutively high levels of the P2X7 cleavage product ( Figure 6A ), which could explain these surprisingly low P2X7 responses in cancer cells despite a high-level receptor expression. Finally, the eATP-evoked cell death of LNCaPs in the LP-buffer was found very low and completely attenuated in the presence of MMP-2-containing serum but enhanced 4-fold by the MMP-2 inhibitor ( Figure 6D ). (Chan et al., 2013) . Following 60 min stimulation with 3 mM ATP, there was very low cell death, which was completely suppressed by the serum (10% DHS) but very significantly enhanced in cells treated with the MMP-2 inhibitor. *P < 0.05, ***P < 0.001. Therefore, this active MMP-2 release appears to be a universal protective mechanism, fine-tuning P2X7 receptor responses in various cell types, allowing stimulation sufficient for promoting growth and survival whilst minimizing pore formation and cell death.
P2X7 inhibition ablates gelatinase activity in mdx skeletal muscle in vivo
Upregulation of P2X7 receptor expression has been documented in a number of muscular dystrophies with an inflammatory component, including DMD and LGMD2b (Rawat et al., 2010; Young et al., 2012; Gazzerro et al., 2015; Sinadinos et al., 2015) . Notably, we have recently demonstrated multifaceted beneficial effects of P2X7 ablation and pharmacological inhibition on DMD pathology . Here, we found that ablation of the P2X7 receptor in mdx mice also results in significant reductions in gelatinase activity in dystrophic skeletal muscles in vivo. Gelatinase activity in mdx muscles was found to be concentrated around populations of infiltrating inflammatory cells but, interestingly, also associated with nuclei of regenerating fibres ( Figure 7A , upper right and inset panels). The significant reduction of this activity in muscles of mdx/P2X7 -/-animals ( Figure 7B ) supports the finding of P2X7-dependent MMP-2 activity and highlights an important new pathological pathway that is ameliorated by P2X7 ablation . In contrast to this in situ activity, western blotting showed no reduction in MMP-2 or MMP-9 protein levels in mdx/P2X7 -/-compared to mdx muscles ( Figure 7C ). In fact, lower levels of MMP-2 were observed in mdx compared to WT lysates, indicating that dystrophic muscle retains the abnormal MMP-2 phenotype found in dystrophic myoblasts (Figure 1 ).
Discussion
Enhanced migratory/invasive behaviour following P2X7 activation led us to the identification of significantly elevated MMP-2 activity in dystrophic muscle cells, where P2X7 itself is upregulated. MMP-2 was released in a P2X7-dependent manner and effected the cleavage of β-dystroglycan and CD44-well-documented orchestrators of cellular attachment and migration. Surprisingly, MMP-2 release was found to coincide with the cessation of P2X7 functions. We demonstrated this to be due to the proteolysis of P2X7 by MMP-2. Based on these results, we propose that P2X7 signalling responses are modulated by a novel feedback loop involving MMP-2-evoked proteolytic processing, rendering the P2X7 non-functional. We demonstrated the universality of this mechanism by confirming it in macrophages and HEK293 cells expressing P2X7. We also demonstrated the clinical relevance of these findings by showing that P2X7 ablation abrogates gelatinase activity in dystrophic muscles in situ. Finally, we showed that Immunoblotting showing that MMP-2 protein levels were actually reduced in mdx compared to WT muscles whilst there was no significant difference between mdx and mdx/P2X7 -/-samples-a result in clear contrast to the activity levels of these enzymes. *P < 0.05.
MMP-2 inhibition triggers death of human cancer cells, which were otherwise unresponsive to eATP stimulation and thus the P2X7-dependent MMP-2 release represents a fine-tuning mechanism for P2X7 receptor functions, imparting the ability to benefit from the P2X7 over-expression for growth and metabolism, whilst protecting against P2X7 LP-induced cell death in the high eATP environment. We propose that P2X7 possesses its own autocrine signalling feedback through MMP-2. We showed that MMP-2 cleavage does not differentiate between pore and channel activity, as both are blocked ( Figure 3E and F) . However, only during the high level or chronic stimulation, the LP becomes activated and MMP-2 is released; hence, MMP-2 activity affects the pore over the Ca 2+ channel function. This provides an elegant system of enzymatic tuning, which can regulate P2X7 signalling in every cell type. Cleavage predictions mapped the MMP-2 sites to residues R277 and 298 ( Figure 5G ). The first region is particularly well conserved across the species (Supplementary Figure S6B) and indeed we found this mechanism operant in human and mouse cells. Moreover, this region has been reported to harbour the P2X7 gain of function mutation, R276A (Thompson et al., 2010) . We therefore hypothesize that this gain of function is conferred through the ablation of this MMP-2 site, as confirmed by CleavPredict and further experiments are underway to ascertain whether cleaved domains of P2X7 retain any function.
Overall, this work provides new insight into the molecular mechanisms of P2X7 function and regulation orchestrating the purinergic signalling (Figure 8) . It is interesting to consider the physiological implications of this mechanism, where P2X7 expressing cells would respond to high eATP differently: the same receptor density on the same cell may produce a significantly different effect in organs with discontinued capillaries (sinusoids) permitting serum proteins, including MMP-2, to leave the bloodstream. Therefore, sinusoids in the liver, endocrine, lymphoid and hematopoietic organs (e.g. spleen and bone marrow) present P2X7 with a working environment entirely different to that in the CNS, sheltered behind the blood-brain barrier. Moreover, in pathological conditions disrupting integrity of blood vessels or BBB functions, P2X7 functions may change significantly.
Moreover, P2X7 has established roles in cell migration and invasion, with notoriety in tumour metastasis, where MMPs have been implicated as downstream mediators of the eATP response (Qiu et al., 2014; Xia et al., 2015) . We have shown inter-dependence of these responses and identified β-dystroglycan as a target. Dystroglycan is also a known component of focal adhesions in myoblasts (Kwan et al., 2004) . Interestingly, we found P2X7-dependent MMP activity associated with central nuclei of regenerating myofibers, which raises questions about its function there; MMP-2 in cardiomyocyte nuclei might cleave PARP, a DNA-repair enzyme (Schwarz et al., 2012) . However, although intracellular MMP-2 activity has been demonstrated, including in skeletal muscles (Hadler-Olsen et al., 2015) , mechanisms governing the balance between intraand extracellular MMP-2 remain elusive (Ali et al., 2012) .
In both skeletal muscles and muscle cells, we found significantly elevated MMP-2 activity, yet MMP-2 protein levels were downregulated compared to WT. Clearly, expression of MMPs cannot be used as an indicator of its activity as the latter is controlled in a complex manner involving the tissue inhibitors of metalloproteinases (TIMPs). However, the release of MMP-2 Figure 8 Mechanism of P2X7-dependent pore formation, MMP-2 activation and its functional consequences. (Left panel) β-dystroglycan binds to α-dystroglycan which interacts with extracellular matrix proteins (e.g.) laminin. CD44 binds to ERM proteins, which in turn bind to actin, forming a link between membrane and cytoskeleton. P2X7 C-terminus associates with Hsp90, which binds to and stabilizes MMP-2. (Right panel) Following sustained P2X7 stimulation the 'LP' response is activated; MMP-2 is released, facilitating β-dystroglycan degradation disrupting links with both intra and extracellular scaffolds. The extracellular CD44 cleavage product may bind to and augments P2X7 function (Michaluk et al., 2007) while MMP-2 activity halts all P2X7 functions through a direct receptor cleavage. correlated with shifting its activity from intra to extracellular compartments, suggesting that it was due to changes in MMP-2 localization and not because of its associated TIMPs. P2X7 expression is upregulated in several human cancers and P2X7 has been implicated in tumour growthpromotion (Di Virgilio et al., 2009; Di Virgilio, 2015) . Intriguingly, cancer cells appear to be able to reap the rewards of elevated P2X7 receptor expression without suffering the consequences of LP-associated cell death. The molecular mechanisms behind this remarkable paradox were a mystery. Here, we show for the first time that cancer cells are able to benefit from the P2X7 tonic stimulation without succumbing to P2X7 toxicity through MMP-2 release causing direct receptor cleavage. cBioportal (Cerami et al., 2012) analysis of P2X7 and MMP-2 expressions in the Cancer Genome Atlas showed upregulation of both mRNAs in all tumour types (Supplementary Figure S7A) with a strong correlation between expression levels in prostate cancers (Supplementary Figure S7B) . Indeed, we have confirmed this P2X7 cleavage in the human LNCaP prostate cancer cells.
In therapeutic terms, we have shown reduced gelatinase activity in areas of infiltrating macrophages in mdx/P2X7 -/-muscles at the height of the pathology in these animals. Therefore, P2X7 antagonism shown to inhibit fibre damage, myogenic cell death and reduce inflammation , also involves MMP inhibition. MMP-9 ablation in mdx mice has documented beneficial effects, with reduced levels of necrosis and neutrophil invasion but only at the acute disease phase (Hindi et al., 2013; Shiba et al., 2015) . Interestingly, MMP-2 ablation has been shown to impair both angiogenesis and myofiber regeneration in mdx model (Miyazaki et al., 2011) . This data highlights the problem with global MMP inhibition. Our results suggest that P2X7 receptor antagonists may offer a targeted alternative to the global MMP antagonism, preventing the serious side effects associated with such treatments (Cathcart et al., 2015) . Receptors are more 'druggable' and several P2X7 antagonists are already available (Bartlett et al., 2014) ; this approach might be applicable to a host of MMPassociated pathologies, including infectious diseases (sepsis), cancer, rheumatoid arthritis, atherosclerosis, inflammation, cardiomyopathy, and, last but not least, muscular dystrophies.
Given that both MMP-2 and MMP-9 gelatinases can be released following P2RX7 stimulation, it is remarkable that MMP-2 knockout exacerbated inflammatory arthritis while MMP-9 knockout reduced it (Itoh et al., 2002; Xue et al., 2014) . Moreover, MMP-2 mutation causes a multicentric osteolysis and arthritis syndrome in humans (Martignetti et al., 2001) . Our data provide molecular insight into this divergence as MMP-2 ablation would eliminate the natural 'off' switch for proinflammatory P2X7.
In conclusion, our results provide a novel mechanistic insight into the molecular signalling pathways associated with the elusive P2X7 LP; the MMP-2 feedback loop we described here represents a first indication of how physiological niches can regulate P2X7 pore function through variations in serum concentration or MMP-2 uptake/release. The implications of this are significant for both immunology and pathology, given the important roles of both P2X7 and metalloproteinases in inflammatory and degenerative disorders (Cauwe and Opdenakker, 2010) . Finally, we postulate that P2X7 functions in vivo can vary significantly between the same cell type located in organs with different serum accessibility, e.g. spleen and brain. This mechanism may also explain why, in tumours, high density of P2X7 in the presence of high eATP does not lead to P2X7-driven cell death.
Materials and methods
Animals
C57BL10, DMD mdx (mdx) and mdx/P2X7 -/- 8-week-old male mice were used in accordance with institutional Ethical Review Board and the Home Office (UK) approvals. All mice were maintained under pathogen-free conditions and in a controlled environment (12 h light/dark cycle, 19°C-23°C ambient temperature, 45%-65% humidity). Mice were killed by CO 2 inhalation and cells and muscles dissected and used for protein extraction, or frozen in isopentane pre-chilled in liquid nitrogen for cryosectioning.
Antibodies and reagents
The following antibodies were used (1:1000): anti-P2X7 (177003, Synaptic Systems), anti-MMP-2 (TP220, Amsbio), anti-MMP-9 (TP221 Amsbio), anti-actin (A2066, Sigma), anti-GAPDH (G9545, Sigma), and anti-HCAM/CD44 (Santa Cruz, sc-18849). Anti-F4/80 (Abcam, ab6640) was used at 1:200 and anti-β-dystroglycan (DSHB, MANDAG2(7D11)) was used at 1:50 dilution. Other reagents used: P2X7 antagonist A438079 (10 μM, Tocris Bioscience), MMP-2 inhibitor I (Millipore). All other chemicals were purchased from Sigma. Agonists were used at concentrations of 3 mM (ATP) and 0.5 mM (BzATP), unless stated otherwise.
Cell culture
Wild-type and dystrophic myoblasts (with a premature stop codon in exon 23 of the Dmd gene) (Browne et al., 2013) were cultured as primary cells in KnockOut DMEM (Invitrogen) supplemented with 10% (v/v) KSR (Knockout Serum Replacement, Invitrogen), 5% (v/v) DHS (Donor Horse Serum, Sera Labs) and 2 mM L-glutamine. Peritoneal macrophages isolated by lavage with 5 ml ice-cold PBS-containing 1% FBS (Sigma) were maintained in 10% (v/v) FBS and 2 mM L-glutamine. Raw264.7 mouse macrophages (ATCC) were cultured as per peritoneal macrophages. LNCaP cells (ATCC; CRL-1740™) were maintained in 50:50 DMEM F12 HAMS, RPMI 1640, supplemented with 10% (v/v) FBS (Sigma) and 2 mM L-glutamine. Following cell culture cells were washed to remove all traces of serum and analysed in an appropriate serum-free assay buffer.
Zymography
For IGZ, all experiments were conducted in serum-free physiological saline buffer (145 mM NaCl, 5 mM KCl, 1 mM MgCl 2 and 10 mM Na-HEPES). Subsequently, cells were scraped in lysis buffer containing 50 mM Tris base, 0.5% (v/v) Triton, pH 7.4. 30-40 g proteins were resolved in 10% poly-acrylamide (29:1) gels containing 2 mg/ml gelatin (Sigma). Gels were washed 3× 30 min in 2.5% Triton-X solution, washed in water, then left in the incubation buffer (50 mM Tris-HCl, 0.15 M NaCl, 10 mM CaCl 2 , pH 8) for 24-48 h. Gels were stained with Coomassie Brilliant Blue G (0.05%), de-stained in 8% AcOH and 4% MetOH and imaged using GelDoc EZ system (Bio-Rad). The protein bands staining intensity was used as a loading control (Supplementary Figure S2) and densitometric analyses were performed using the integrated density measurement function of the ImageJ software (Schindelin et al., 2012) . Ex vivo, in situ zymography was performed on 10 μm cryosections of TA muscles. Muscle sections adhered to glass slides were rehydrated in IGZ incubation buffer (as above), DQTM Gelatin (0.2 mg/ml) was added and sections were left overnight at 37°C and images were captured using LSM710 confocal (Zeiss). Cleavage site prediction was performed using CleavPredict (Sandford Burnham).
Western blotting
Proteins were extracted from adherent cells by scraping in 100 μl ice-cold extraction buffer containing 1× LysisM (Roche, 04719956001), 1× cOmplete ULTRA Mini EDTA-free protease inhibitor cocktail tablet (Roche, 05892791001), 1× PhosSTOP phosphatase inhibitor cocktail tablet (Roche, 04906845001), 2 mM sodium orthovanadate (Sigma, S6508). Cells were disrupted by passing 10 times through a 25 g needle followed by centrifugation for 30 sec at 800× g. Total proteins from frozen tissues were extracted in ice-cold extraction buffer (as above) using 50 passes in a glass Teflon homogenizer (Fisher Scientific, 11592543) . Samples were centrifuged (800× g for 3 min at 4°C) to remove debris and concentrations determined using the Bicinchoninic acid assay kit (Sigma, B9643). Twenty to 40 μg protein was mixed with Laemmli buffer at 1:1 (v/v) ratio with 2.5% (v/v) β-mercaptoethanol, heated for 5 min at 95°C, then chilled on ice prior to gel loading. Samples were separated on Any-Kd Mini-protean TGX ready gels (Bio-Rad, 456-9034) and electro-blotted onto Hybond-P membranes (GE Healthcare, RPN303F). Blots were blocked in 5% (w/v) non-fat milk powder in 1× Tris buffered saline (TBST; 50 mM Tris, 150 mM NaCl, 0.01% (v/v) Tween-20, Sigma T1503, S7653 and P1379, respectively), for 1 h prior to probing with primary antibody diluted in the same blocking buffer (overnight at 4°C or 2 h at room temperature), then washed (3 times) with 1× TBST for 10 min and incubated with the appropriate horseradish peroxidase-conjugated secondary antibody; anti-mouse 1:10000 (Sigma, A4416), antirabbit 1:5000 (Sigma, A6154) overnight at 4°C or 1 h at room temperature. Specific protein bands were visualized using Luminata Classico or Forte chemiluminescent substrates (Merck Millipore, WBLUC0500 and WBLUF0500, respectively), images were obtained using a ChemiDoc MP system (Bio-Rad). Densitometric analyses were performed using the integrated density measurement function of ImageJ software. All experiments were repeated at least three times in triplicate throughout.
LP and cell death assays
For dye uptake assays, cells were incubated in the LP buffer (145 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , and 10 mM Na-HEPES) containing 5 μM ethidium bromide (EtBr). Following addition of agonists, EtBr uptake was analysed under LSM510 confocal microscope (Zeiss) with heated stage and a dipping objective, or using POLARstar Optima plate reader (BMG Labtech). Cell death was assessed by LDH release, measured using in vitro toxicology assay kit (Sigma) as described in Young et al. (2015) .
Intracellular Ca
2+ measurements
Muscle cells were cultured on glass coverslips in a 6-well plate (500000 cells/well) for 48 h under conditions described above. Cells (70%-80% confluent) were loaded with Fura-2 AM (Molecular Probes) in culture medium for 15 min at 37°C in a 95% O 2 , 5% CO 2 atmosphere. After two brief washes in the assay buffer (5 mM KCl, 1 mM MgCl 2 , 0.5 mM Na 2 HPO 4 , 25 mM HEPES, 130 mM NaCl, 1 mM pyruvate, 5 mM D-glucose, and 2 mM CaCl 2 ; pH 7.4), the coverslips were mounted in a cuvette and maintained in the assay buffer at room temperature in RF5301PC spectrofluorimeter (Shimadzu). Fluorescence was recorded at 510 nm with excitation at 340/380 nm. At the end of each experiment, the Fura-2 fluorescence was calibrated by addition of 13 μM ionomycin to determine maximal fluorescence. Each experiment was repeated at least five times.
Data analysis and statistics
Results are reported as means ± standard deviation where n refers to number of independent experiments (Rigato et al., 2012; Browne et al., 2013; Young et al., 2015; Pippel et al., 2017) . For statistical analysis, a one-way analysis of variance was performed with the post hoc Tukey's test (Microcal Origin 7.0). The differences were considered statistically significant at P < 0.05.
Supplementary material
Supplementary material is available at Journal of Molecular Cell Biology online.
